Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Early cancer detection is the golden key
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(34)
•••
Comment by Skrit37on Dec 31, 2020 6:11am
265 Views
Post# 32201805

RE:Early cancer detection is the golden key

RE:Early cancer detection is the golden key
BoredAccountGuy wrote:
take a look at this article. 8 billion USD for a company that does the exact same thing as StageZero yet StageZero is further ahead in the development. https://grail.com/press-releases/illumina-to-acquire-grail-to-launch-new-era-of-cancer-detection/



Lets remeber Illumina basically re purchesed their own company back ...so the 8bill is out to lunch IMO... is not a fair evaluation...there are many reasons why you would want to inflate the price...fact is.... there is, and always was a strong connection between the two companies without diving into it further

Its better comparing Exact Sciences purchase of both Thrive(2.15b) and Base Genomics(410b) for an approx total of 2.55billion with no prior connection as far as i know

So no matter which way you look at it..we are way undervalued for sure seeing Aristotle has already been proven via the sentinal princible and commercialization is literally right around corner

goodluck folks

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities